A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study

Oliver Weigert Department of Internal Medicine III, University of Munich, Munich, GermanyCorrespondence[email protected]

, MD,

Eckhart Weidmann Department of Internal Medicine II, Hospital Nordwest, Frankfurt, Germany

Rudolf Mueck Department of Internal Medicine II, Diakonie Hospital, Stuttgart, Germany

Martin Bentz Department of Internal Medicine II, Hospital of Karlsruhe, Karlsruhe, Germany

Christoph von Schilling Department of Internal Medicine III, Hospital of Freising, Technical University of Munich, Munich, Germany

Robert Rohrberg Clinic for Hematology/Oncology, Halle, Germany

Kathleen Jentsch-Ullrich Department of Internal Medicine, University of Magdeburg, Magdeburg, Germany

Wolfgang Hiddemann Department of Internal Medicine III, University of Munich, Munich, Germany

Martin Dreyling Department of Internal Medicine III, University of Munich, Munich, Germany

Your download is now in progress and you may close this window